My laboratory interests also include understanding the c-MET axis in the tumor microenvironment in ovarian cancer as well as the biology of mucinous neoplasms of ovarian/appendiceal and colonic origins. I received the American Society for Clinical Oncology Young Investigator Award in 2011-2012 to fund a project designed to rationally choose in an unbiased fashion appropriate combinations of targeted agents for the treatment of recurrent ovarian cancer.
I love being at the OSUCCC – James. I work in the company of first-class physicians, all experts in their respective fields of study. We collaborate on new therapies and treatments for all types of cancer, and together we accomplish so much. Being in the academic environment of The Ohio State University also allows me to share my knowledge with students as an assistant professor of internal medicine in the College of Medicine.
University of Texas Medical Branch
Wake Forest Baptist Medical Center
7/1/2006 - 6/30/2008
Specialties and conditions I treat
- Medical Oncology
- Ovarian Cancers
- Peritoneal Cancers
- Colorectal Cancers
- Cecal Cancer
- Appendix Cancer
- Small Intestine Cancer
Locations where I practice
The James at Martha Morehouse Medical Plaza
More about my work
National Cancer Institute
7/1/2008 - 6/30/2012
American Board of Internal Medicine
American Board of Internal Medicine (Subspecialty: Medicine Oncology)
News about me
Consulting and Related Relationships
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 03/28/17, Dr. Hays has reported no financial relationships with medical device, research and/or drug companies.